The global oral rehydration salt (ORS) market was valued at USD 2,184 million in 2025 and is projected to grow from USD 2,338 million in 2026 to USD 4,008 million by 2034 at a CAGR of 6.97% during the forecast period (2026–2034). North America dominated the oral rehydration salt market with a market share of 31.46% in 2025.
Oral rehydration salts are scientifically balanced mixtures of glucose and essential electrolytes, primarily sodium chloride, potassium chloride, and sodium citrate, formulated to maximize intestinal water absorption and restore electrolyte balance. These life-saving medical preparations provide an effective, low-cost treatment for severe dehydration caused by acute gastroenteritis, diarrheal illnesses, and excessive fluid loss.
The oral rehydration salt market demand is driven by the high global prevalence of dehydrating illnesses, particularly among pediatric and geriatric populations in developing and emerging regions. Public health initiatives promoting proper hydration management and the rising consumer awareness regarding advanced electrolyte maintenance are also contributing to oral rehydration salt market growth.
Download a Free Sample To learn more about this report,
The oral rehydration salt market is exposed to supply chain disruptions because it depends on globally sourced active pharmaceutical ingredients such as potassium chloride and specialized laminated packaging materials. Disruptions in the availability of these critical raw materials increase manufacturing lead times, elevate production costs, and threaten the continuous distribution of life-saving hydration therapies to vulnerable populations. On a global scale, pharmaceutical formulators are responding by establishing long term localized supply contracts, developing shelf stable powder formulations to reduce storage dependencies, and investing in advanced inventory monitoring systems. The market is expected to follow a V-shaped recovery, as the critical clinical demand for these essential health goods drives a rapid rebound in production volumes once temporary raw material constraints ease.
Diversification Toward Patient- and Setting-Specific ORS Presentations
The ORS market is moving beyond a single standardized presentation toward sachet sizes and configurations suited to different treatment volumes, patient groups, and delivery settings. Smaller-volume presentations can reduce preparation requirements and wastage, while flavored variants can improve acceptability. This is encouraging suppliers to broaden product configurations around practical treatment requirements rather than relying exclusively on conventional large-volume sachets.
Shift Toward Ready-to-Use and Convenient ORS Formats
ORS product development is increasingly addressing the practical limitations associated with powder reconstitution by moving toward ready-to-drink and other simplified administration formats. These products can reduce preparation steps and make administration easier in settings where measuring, dissolving, or storing reconstituted ORS is inconvenient. This is creating a product-development pathway focused specifically on administration convenience rather than changes in the therapeutic role of ORS.
The oral rehydration salts (ORS) and electrolyte hydration market forecasts accelerated capital deployment as consumer demand shifts away from high-sugar legacy sports drinks toward clean-label, medical-grade hydration formulations.
Key Investment and Funding Activities in Oral Rehydration Salt (ORS) Market, 2026
Hydration Pharmaceuticals (Hydralyte)
~USD 260,000
In June 2026, Hydration Pharmaceuticals (owner of the Hydralyte brand in the U.S.) raised ~USD 260,000 via a share placement to fund the e-commerce expansion and operational turnaround of its medical-grade oral rehydration products.
KinderFarms (Kinderlyte)
USD 4.0 Million
In March 2026, KinderFarms secured a USD 4.0 million funding round to aggressively scale the national retail distribution of its Kinderlyte product line, a clean-ingredient, medical-grade oral rehydration solution (ORS).
Persistent Diarrheal Disease Burden and Public-Health Treatment Demand Drive Market
The persistent global burden of diarrheal disease creates a fundamental demand base for ORS because dehydration remains the principal immediate risk requiring fluid and electrolyte replacement. WHO identifies diarrheal disease as a major global cause of illness, with young children particularly vulnerable to dehydration-related complications. This sustains recurring demand across households, pharmacies, primary healthcare facilities, and institutional treatment programs.
Expansion of public-health treatment programs is further supporting ORS consumption by incorporating oral rehydration into childhood diarrhea management and outbreak-response activities. For instance, India's Central Procurement Branch issued a rate contract for ORS powder and zinc tablets for its Intensified Diarrhea Control Fortnight (IDCF) campaign in December 2025, demonstrating how government-led diarrhea-control programs directly generate institutional demand for ORS.
Regulatory Compliance and Supply-Side Constraints Limit Market Expansion
Mandatory pharmaceutical registration and manufacturing compliance can limit ORS market entry because manufacturers must meet pharmaceutical-quality, GMP, formulation, testing, labeling, and registration requirements before commercialization. These requirements can increase compliance costs and extend the time required for new suppliers to enter regulated markets.
Dependence on quality-assured manufacturing capacity can constrain ORS supply because the number of manufacturers capable of consistently meeting pharmaceutical-quality requirements is limited in some procurement markets. This can make the market more vulnerable to production disruptions and restrict the ability of buyers to rapidly replace suppliers when capacity is unavailable. For instance, UNICEF's 2026 ORS market assessment identified a relatively small pool of suppliers meeting international quality requirements, highlighting the limited supplier diversification available to large-scale purchasers.
Local Production and Channel Expansion Offer Growth Opportunities
Local ORS manufacturing is creating opportunities for pharmaceutical manufacturers in high-burden countries to establish domestic production and participate more directly in government, NGO, and healthcare procurement. Local production can shorten replenishment cycles, reduce import dependence, and improve responsiveness during seasonal diarrhea peaks and outbreaks. For instance, Sam-Ace in Nigeria manufactures WHO-registered ORS locally, demonstrating how domestic pharmaceutical manufacturers can build supply capacity for essential rehydration products in African markets.
Expansion of pharmacy and digital-health distribution is creating opportunities for ORS manufacturers and healthcare retailers to improve product availability beyond conventional hospital and government channels. Digital ordering and organized pharmacy networks can make ORS easier to locate and purchase during short-duration dehydration episodes, particularly in urban and digitally connected markets. This provides suppliers with an additional route to reach consumers without depending exclusively on institutional procurement or physical healthcare facilities.
Last-Mile Supply Gaps and Treatment Adherence Challenge Market Growth
Persistent stock-outs at healthcare facilities and the community level can prevent ORS from reaching patients when treatment is needed, particularly in remote and high-burden areas. Fragmented distribution networks, long replenishment cycles, and difficult transportation conditions can therefore create a gap between national supply availability and actual patient access.
Inconsistent adherence to recommended diarrhea-treatment practices can also limit effective ORS utilization even when products are available. Caregivers may delay treatment, prepare the solution incorrectly, discontinue administration, or fail to follow recommended treatment protocols. For instance, UNICEF data indicate that only around 22% of children with diarrhea receive combined ORS and zinc treatment, highlighting the substantial gap between recommended therapy and actual treatment uptake.
The powder segment accounted for a share of 58.25% in 2025, driven by cost-effectiveness and extended shelf life. These single-serve sachets remain the primary choice for emergency relief programs and low-income healthcare setups worldwide. Heavy reliance on these stable formulations for widespread distribution ensures its sustained market dominance.
The solutions segment is expected to grow at a CAGR of 7.15% during the forecast period, fueled by consumer preference for immediate consumption formats. The demand for pre-mixed flavored solutions is particularly strong among urban consumers seeking convenience.
Request Customizationto receive a tailored report.
The children segment accounted for a share of 52.45% in 2025, supported by the high vulnerability of pediatric demographics to severe dehydration. World Health Organization guidelines heavily emphasize early rehydration therapy in infants and young children to reduce hospitalization rates.
The adults segment is expected to grow at a CAGR of 7.25% during the forecast period, propelled by expanding awareness regarding hydration during travel and strenuous activities. The emphasis on workplace wellness and active lifestyle maintenance is driving higher daily usage among working professionals.
The diarrheal treatment segment is expected to grow at a CAGR of 6.85% during the forecast period, supported by the critical need to manage fluid loss from gastrointestinal infections. Widespread distribution of low-osmolarity formulations by global health organizations drives segment growth.
The general dehydration segment is expected to grow at a CAGR of 7.35% during the forecast period, propelled by increasing sports participation and rising heat-related illnesses. The continuous introduction of flavored hydration products in summer temperatures and climate-induced heatwaves also accelerate segment growth.
The retail pharmacies segment accounted for a share of 46.50% in 2025, driven by the widespread accessibility and essential role in dispensing over-the-counter medications. Critical reliance on direct consumer access strengthens its current market leadership.
The online pharmacies segment is expected to grow at a CAGR of 7.55% during the forecast period, fueled by expanding e-commerce penetration and the demand for doorstep deliveries. Strategic investments in digital pharmacy platforms also drive segment growth.
Speak to an Analystto discuss market opportunities.
North America: Market Dominance Led by Established Consumer Healthcare Practices and Broad Clinical Use of ORS
The North America Oral Rehydration Salt (ORS) market accounted for the largest regional share of 31.46% in 2025. The region's leading position is supported by established healthcare infrastructure, widespread awareness of electrolyte replacement, and the availability of ORS products through pharmacies, hospitals, and consumer healthcare channels.
The US Oral Rehydration Salt (ORS) market was valued at USD 592 million in 2025. Demand is supported by established clinical use of oral rehydration solutions for dehydration associated with acute diarrheal illness and foodborne infections. The Centers for Disease Control and Prevention (CDC)'s 2025 clinical guidance recommends oral rehydration solutions when severe diarrhea creates dehydration risk, reinforcing their role in acute gastrointestinal illness management. This established clinical application, combined with broad consumer access to rehydration products, supports the country's substantial market base.
The Canada Oral Rehydration Salt (ORS) market was valued at USD 95 million in 2025, supported by the use of oral rehydration solutions for dehydration associated with diarrheal illness, including travel-related gastrointestinal infections. Canada's public-health guidance specifically recommends oral rehydration solutions for moderate-to-severe travelers’ diarrhea, particularly where dehydration presents a greater risk. The combination of travel-health applications and use among vulnerable populations supports steady demand for ORS products in Canada.
Asia Pacific: Fastest Growth Driven by Persistent Diarrheal Disease Burden and Expansion of Accessible Community-level Rehydration Treatment
The Asia Pacific Oral Rehydration Salt (ORS) market is projected to expand at a CAGR of 7.63% during the forecast period, showcasing the fastest regional growth. This growth is supported by the continued need for affordable and accessible treatment for dehydration, particularly among children, alongside improvements in primary healthcare access and community-based disease management.
The China Oral Rehydration Salt (ORS) market was valued at USD 328 million in 2025, fueled by clinical management of acute gastroenteritis and dehydration. China's 2025 National Health Commission clinical protocol for norovirus gastroenteritis identifies oral rehydration as the preferred approach for mild-to-moderate dehydration and emphasizes early fluid and electrolyte replacement. The 2026 National Essential Medicines List includes ORS in powder formulations I, II, and III. The integration of ORS into clinical guidance and the essential-medicine framework strengthens its institutional demand base in China.
The Japan Oral Rehydration Salt (ORS) market was valued at USD 118 million in 2025. According to Japan’s Ministry of Health, Labour and Welfare, occupational heatstroke cases reached 1,803 in 2025, an approximately 43% increase from 2024 and the highest level since records began, reinforcing the need for ORS solutions. Otsuka Pharmaceutical’s OS-1 is marketed specifically for dehydration associated with heatstroke and excessive sweating, supporting the use of ORS products during periods of elevated heat exposure.
The India Oral Rehydration Salt (ORS) market was valued at USD 364 million in 2025. ORS demand is strongly associated with childhood diarrhea management and the need for accessible treatment at community and primary-care levels. India's STOP Diarrhea Campaign 2026 provides children under five with ORS and zinc as part of its diarrhea-management strategy, while campaign guidance supports ORS availability through health facilities. This direct public-health distribution channel provides a strong institutional mechanism for expanding ORS access and consumption in India.
The oral rehydration salt market competitive landscape is moderately concentrated, featuring pharmaceutical manufacturers, global healthcare enterprises, and specialized consumer health brands competing to deliver precise fluid and electrolyte replacement solutions. Established players compete through extensive distribution networks, stringent clinical formulation standards aligned with WHO guidelines, and affordable mass-production capabilities. Emerging players differentiate themselves through flavor-enhanced formulations, low-sugar profiles, and convenient portable stick packs tailored for daily wellness and active lifestyles.
May 2026: UNICEF's MENA (Middle East and North Africa) Regional Office issued a Request for Expression of Interest (REOI) to identify qualified pharmaceutical manufacturers and suppliers for a planned procurement exercise covering low-osmolarity Oral Rehydration Salts (ORS), including 20.5 g/1 L and 15.4 g/0.75 L presentations.
April 2026: Liquid I.V. announced a multi-year strategic partnership with McLaren Racing, becoming the Official Partner for the McLaren Mastercard Formula 1 Team, F1 Academy, and Arrow McLaren IndyCar Team in North America to supply advanced functional hydration solutions.
March 2026: Cipla Health Limited executed a product launch to expand its ProlyteORS portfolio with a new Masala Guava flavor. The product maintains the exact WHO-recommended ORS formulation.
Customize This Report to Match Your Strategic Objectives
Author's Details
Research Analyst
Devyani Desale is an F&B research professional with 2+ years of experience in market intelligence, specializing in market analysis, secondary research, market estimation, and forecasting across the food and beverage sector. She provides actionable insights into market dynamics, industry trends, competitive landscapes, and emerging growth opportunities to support strategic business decision-making.
Her expertise includes assessing market size, growth potential, competitive scenarios, consumer trends, and industry developments through structured research and analytical methodologies. She focuses on translating market data into clear, relevant insights that support business strategy and informed decision-making.
Kaempferol Market Size, Share, Growth, Analysis, Report, 2034
Glutamine Market Size, Share, Growth, Analysis, Report, 2034
Liquid Dietary Supplements Market Size, Share, Growth, Analysis, 2034
Wellness Supplements Market Size, Share, Growth, Analysis, 2034
Yeast Beta-glucan Market Size, Share, Growth, Forecast, 2034
Weight Loss and Weight Management Diet Market Size, 2034
We are featured on:
sales@straitsresearch.com